1. Howlader N NA, Krapcho M, Miller D, et al.(eds) SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2017/[Last accessed on July 27, 2023].
2. Chronic lymphocytic leukemia. [Updated 2023 Jan 15]. In: StatPearls [Internet];Mukkamalla,2023
3. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity;Wilson;Lancet Oncol,2010
4. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets;Souers;Nat Med,2013
5. "Center for Drug Evaluation and Research - Application 208573Orig1s000 - Division Director Summary Review" (PDF). U.S. Food and Drug Administration (FDA). 2016.